EuRSV - Eubiologics
Alternative Names: RSV-1; RSV-1/2; RSV-2Latest Information Update: 22 May 2024
At a glance
- Originator EUPOP Life Sciences
- Developer EuBiologics
- Class Respiratory syncytial virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 14 May 2024 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in South Korea (IM) (NCT06216093)
- 25 Jan 2024 EuBiologics plans a phase I trial for Respiratory syncytial virus infections (Prevention) in March 2024 (IM) (NCT06216093)
- 25 Jan 2024 EuBiologics and POP Biotechnologies form a joint venture to co-develop EuRSV vaccine